The cream in 0. 1 cream is a powerful topical retinoid that has gained recognition in the field of dermatology for its effectiveness in the treatment of various skin conditions. Derived from vitamin A, the Tazaroteno in Cream 0. 1 presents powerful ant i-inflammatory and antiproliferative properties, which makes it an invaluable tool to treat conditions such as acne, psoriasis and photoenvexing.
The mechanism of action of the Tazaroteno in Cream 0. 1 consists in the modulation of cell differentiation and keratinization, which leads to a decrease in inflammation and an increase in cell renewal. This topical medicine selectively binds to retinoic acid receptors, subsequently influencing gene expression and interrupting abnormal growth patterns observed in various dermatological disorders.
According to clinical studies, the topical application of Tazaroteno Cream 0. 1 has demonstrated significant efficacy in reducing acne lesions, improving the size and severity of psoriatic plaques and the decrease in fine lines and wrinkles associated withPhotoengation.
A key advantage of 0. 1 tazarot o-ethical cream lies in its formulation, which guarantees optimal penetration and absorption in the skin. This cream is formulated with a unique vehicle that improves stability, bioavailability and compliance by the patient. In addition, it has a low potential of systemic side effects due to its minimum systemic absorption, offering an excellent security profile for lon g-term use.
| Treated conditions | Effectiveness |
|---|---|
| Acne | Significantly reduces injury and inflammation |
| Psoriasis | Improves the size and severity of the plates |
| Photoengation | Decreases expression lines and wrinkles |
Although Tazaroteno 0. 1 cream offers notable benefits, it is essential to keep in mind that this medicine can cause local irritation, dryness and erythema, especially during the initial phase of the treatment. To minimize these adverse effects, it is recommended to start with a lower concentration or adjust the application frequency.
